Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?
作者信息
Khawaja Fareed, Chemaly Roy F
机构信息
Department of Infectious Diseases, Infection Control and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
出版信息
Bone Marrow Transplant. 2022 May;57(5):701-702. doi: 10.1038/s41409-022-01616-7. Epub 2022 Feb 26.
Abstract
摘要
相似文献
1
Predicting risk of progression to lower respiratory tract infection in allogeneic hematopoietic cell transplant recipients with respiratory viral infections: where are we now?
Bone Marrow Transplant. 2022 May;57(5):701-702. doi: 10.1038/s41409-022-01616-7. Epub 2022 Feb 26.
2
Correlation of initial upper respiratory tract viral burden with progression to lower tract disease in adult allogeneic hematopoietic cell transplant recipients.
J Clin Virol. 2022 Jun;150-151:105152. doi: 10.1016/j.jcv.2022.105152. Epub 2022 Apr 4.
3
Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients.
Biol Blood Marrow Transplant. 2018 Nov;24(11):2293-2301. doi: 10.1016/j.bbmt.2018.05.016. Epub 2018 May 16.
4
Predictive Value of Respiratory Viral Detection in the Upper Respiratory Tract for Infection of the Lower Respiratory Tract With Hematopoietic Stem Cell Transplantation.
J Infect Dis. 2020 Jan 14;221(3):379-388. doi: 10.1093/infdis/jiz470.
5
Respiratory syncytial virus and human metapneumovirus after allogeneic hematopoietic stem cell transplantation: Impact of the immunodeficiency scoring index, viral load, and ribavirin treatment on the outcomes.
Transpl Infect Dis. 2020 Aug;22(4):e13276. doi: 10.1111/tid.13276. Epub 2020 Apr 6.
6
Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Haematologica. 2019 Jul;104(7):1322-1331. doi: 10.3324/haematol.2018.215152. Epub 2019 Jun 20.
7
Effective use of oral ribavirin for respiratory syncytial viral infections in allogeneic haematopoietic stem cell transplant recipients.
J Hosp Infect. 2017 Feb;95(2):214-217. doi: 10.1016/j.jhin.2016.11.012. Epub 2016 Nov 25.
8
Successful systemic high-dose ribavirin treatment of respiratory syncytial virus-induced infections occurring pre-engraftment in allogeneic hematopoietic stem cell transplant recipients.
Transpl Infect Dis. 2013 Aug;15(4):435-40. doi: 10.1111/tid.12092. Epub 2013 May 20.
9
Respiratory syncytial virus infection following hematopoietic stem cell transplantation.
Bone Marrow Transplant. 2002 Feb;29(4):321-7. doi: 10.1038/sj.bmt.1703365.
10
Novel factors to predict respiratory viral disease progression in allogeneic hematopoietic cell transplant recipients.
Bone Marrow Transplant. 2022 Apr;57(4):649-657. doi: 10.1038/s41409-022-01575-z. Epub 2022 Feb 16.
本文引用的文献
1
Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.
N Engl J Med. 2022 Feb 10;386(6):509-520. doi: 10.1056/NEJMoa2116044. Epub 2021 Dec 16.
2
Evaluation of prognostic scores for respiratory syncytial virus infection in a French multicentre cohort of allogeneic haematopoietic stem cell transplantation recipients.
Bone Marrow Transplant. 2021 Dec;56(12):3032-3041. doi: 10.1038/s41409-021-01462-z. Epub 2021 Sep 21.
3
COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey.
Leukemia. 2021 Oct;35(10):2885-2894. doi: 10.1038/s41375-021-01302-5. Epub 2021 Jun 2.
4
Risk factors for seasonal human coronavirus lower respiratory tract infection after hematopoietic cell transplantation.
Blood Adv. 2021 Apr 13;5(7):1903-1914. doi: 10.1182/bloodadvances.2020003865.
5
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial of Presatovir for the Treatment of Respiratory Syncytial Virus Upper Respiratory Tract Infection in Hematopoietic-Cell Transplant Recipients.
Clin Infect Dis. 2020 Dec 31;71(11):2777-2786. doi: 10.1093/cid/ciz1166.
6
Respiratory syncytial virus in hematopoietic cell transplant recipients and patients with hematologic malignancies.
Haematologica. 2019 Jul;104(7):1322-1331. doi: 10.3324/haematol.2018.215152. Epub 2019 Jun 20.
7
Oral Versus Aerosolized Ribavirin for the Treatment of Respiratory Syncytial Virus Infections in Hematopoietic Cell Transplant Recipients.
Clin Infect Dis. 2019 May 2;68(10):1641-1649. doi: 10.1093/cid/ciy760.
8
Risk Factors for Parainfluenza Virus Lower Respiratory Tract Disease after Hematopoietic Cell Transplantation.
Biol Blood Marrow Transplant. 2019 Jan;25(1):163-171. doi: 10.1016/j.bbmt.2018.08.021. Epub 2018 Aug 25.
9
A 5-Year Prospective Multicenter Evaluation of Influenza Infection in Transplant Recipients.
Clin Infect Dis. 2018 Oct 15;67(9):1322-1329. doi: 10.1093/cid/ciy294.
10
Clinical Significance of Human Coronavirus in Bronchoalveolar Lavage Samples From Hematopoietic Cell Transplant Recipients and Patients With Hematologic Malignancies.
Clin Infect Dis. 2017 Jun 1;64(11):1532-1539. doi: 10.1093/cid/cix160.
Zotero 插件